[Pharmacologic regression of cardiac and vascular structural changes in the hypertensive patient. A question that goes beyond the exclusive medical bias].
Antonio Francischetti
E
E
Laboratório de Fisiopatologia Clínica e Experimental, Clinex, Seção de Hipertensão, Metabolismo e Nutrição, UERJ.
Genelhu Fagundes
V
V
Francischetti
A
A
D000328:Adult; D000368:Aged; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000818:Animals; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001161:Arteriosclerosis / Q000150:complications / Q000188:drug therapy; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D003331:Coronary Vessels / Q000473:pathology*; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy*; D017379:Hypertrophy, Left Ventricular / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D009206:Myocardium / Q000473:pathology*; D051381:Rats; D016276:Ventricular Function
D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D002121:Calcium Channel Blockers
Regressão farmacológica das alterações estruturais cardíacas e vasculares do hipertenso. Uma questão que vai além do viés médico exclusivo.